Lipoprotein(a) levels in systemic lupus erythematosus

J Rheumatol. 1994 Feb;21(2):220-3.

Abstract

Objective: To determine lipoprotein(a) [Lp(a)] levels in systemic lupus erythematosus (SLE) and its possible correlation with thrombosis, disease activity, anticardiolipin antibodies (aCL) and steroid therapy.

Methods: Serum Lp(a) levels were determined by radioimmunoassay (RIA) in 34 Caucasian patients with SLE and compared to 66 healthy subjects.

Results: In patients with SLE Lp(a) levels were higher than in controls (42 +/- 35 vs 26 +/- 25 mg/dl, p = 0.01). Lp(a) levels were high (> or = 30 mg/dl) in 56% of the patients with SLE and in 30% of controls (p = 0.02) but were not correlated with the clinical and laboratory findings.

Conclusions: Lp(a) levels are significantly higher in patients with SLE and are not influenced by disease activity, thrombosis, aCL and steroid therapy.

MeSH terms

  • Adult
  • Antibodies, Anticardiolipin / blood
  • Female
  • Humans
  • Lipoprotein(a) / blood*
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / immunology
  • Lupus Nephritis / blood
  • Lupus Nephritis / etiology
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Proteinuria / blood
  • Proteinuria / etiology
  • Risk Factors
  • Thrombosis / blood
  • Thrombosis / etiology
  • Vasculitis / blood
  • Vasculitis / etiology

Substances

  • Antibodies, Anticardiolipin
  • Lipoprotein(a)
  • Prednisone